Reuters logo
BRIEF-KURA ONCOLOGY ‍CONFIRMS PARTIAL RESPONSES OBSERVED IN PATIENTS WITH HRAS MUTANT HNSCC IN TRIAL
October 27, 2017 / 4:53 PM / a month ago

BRIEF-KURA ONCOLOGY ‍CONFIRMS PARTIAL RESPONSES OBSERVED IN PATIENTS WITH HRAS MUTANT HNSCC IN TRIAL

Oct 27 (Reuters) - Kura Oncology Inc

* KURA ONCOLOGY LEAD CANDIDATE TIPIFARNIB SHOWS DURABLE ANTI-TUMOR ACTIVITY IN HRAS MUTANT HEAD AND NECK CANCER IN AACR-NCI-EORTC UPDATE

* ‍CONFIRMED PARTIAL RESPONSES OBSERVED IN FOUR OUT OF SIX PATIENTS WITH HRAS MUTANT HNSCC IN TRIAL​

* BASED ON POSITIVE RESULTS FROM PHASE 2 TRIAL, CO PLANS TO INITIATE A REGISTRATION-ENABLING STUDY IN HRAS MUTANT HNSCC IN 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below